When: Confirmed test and hold of 200 SMA at $57.50 with bullish daily divergence AND no further CAR-T escalation

Then: Add 25% of intended incremental size

When: Close below 200 SMA ($57.50) on volume

Then: Full exit — deeper fundamental deterioration

Trim 20-25% of position around 64.40, tighten hard stop to 63.00, maintain core exposure and dividend yield, wait for confirmed re-entry on reclaim of 66.20 or successful retest of 63.13 with bullish reversal pattern and volume confirmation.

• RSI collapsed from 72.79 on August 4th to 45.53 today—not mean reversion but momentum breakdown across five weeks
• MACD bearish crossover occurred around September 4th or 5th with histogram now at minus 0.47, flipped from positive two weeks ago
• Price below both 10 EMA at 66.20 and Bollinger middle band at 66.23—below every short-term trend reference
• Current stop at 62.89 is exactly one ATR below current price at 64.41, positioned to get hit on any single normal trading session
• Stop at 62.89 sits below 50 SMA at 63.13, assuming support breaks while committing capital as if it holds—worst of both worlds
• Forward P/E of 9.82x reflects analyst estimates with 44% forward EPS growth driven by Q4 2025 charge normalization, not operational expansion
• PEG ratio of 2.5 indicates analysts pricing in optimistic assumptions on optically inflated earnings
• Annualized dividends of 5.16 billion against TTM free cash flow of 8.11 billion means dividend consumes approximately 64% of free cash flow
• Deleveraging positive but absolute debt still 45 billion with debt-to-equity ratio of 201%, creating stress scenario vulnerability
• Eliquis and Revlimid patent expirations represent high magnitude risk with worsening trend, core cash flow engine facing structural headwind starting 2026
• Forward P/E compressed to 9.82x because market correctly pricing multiple structural headwinds: patent, leverage, and pricing pressure risks
• BMY closed down 1.87% on flat tape day with WSJ grouping BMY with Novartis on autoimmune CAR-T deaths—reputational damage is real regardless of clinical correctness
• CAR-T pause creates class-wide regulatory risk—BMY in blast radius if FDA issues modality-wide guidance
• Measured move target on 50 SMA failure: 60.40; longer-term target: 200 SMA at 57.50, representing 4 to 7 dollars of downside from 64.41
• Recommended trim: 20 to 25 percent of position around 64.40, re-entry at 63.13 only on bullish reversal candle confirmation

→ vs aggressive: Framing 11-point RSI drop as 'mean reversion event' ignores that RSI went from 72.79 to 45.53—a collapse from overbought to neutral, not gentle equilibrium return

→ vs aggressive: Calling stop at 62.89 a 'compelling' risk-to-reward ratio ignores it sits exactly one ATR below price and below the 50 SMA at 63.13, assuming support fails while betting capital as if it holds

→ vs aggressive: Treating 9.82x forward P/E as fact when it's an analyst estimate with 44% EPS growth driven by non-recurring Q4 2025 charge normalization rather than operational expansion

→ vs aggressive: Using PEG ratio of 2.5 to support valuation ignores that 2.5 reflects optimistic analyst assumptions on optically inflated earnings that require stripping out impairments to look attractive

→ vs aggressive: Leaning on 3.9% dividend yield as 'income floor' ignores that annualized dividend of 5.16 billion consumes 64% of TTM free cash flow of 8.11 billion, making it a discretionary item under stress

→ vs aggressive: Completely glossing over Eliquis and Revlimid patent cliff—high magnitude risk with worsening trend that's the cash flow engine walking out the door starting 2026

→ vs aggressive: Dismissing CAR-T autoimmune risk as 'responsible safety management' ignores market reality: BMY down 1.87% on flat tape, grouped by WSJ with Novartis on deaths, facing class-wide regulatory blast radius

→ vs aggressive: Recommending to add at current levels violates the trader's own framework of waiting for 10 EMA reclaim at 66.20, adding into broken momentum without confirmation

HOLD with modified parameters: maintain current exposure, do not add into broken momentum, do not trim aggressively ahead of catalyst, set stop at $62.75

• HOLD is correct; maintain current exposure rather than adding or trimming aggressively
• $50 SMA at $63.13 is the binary decision point where the structural uptrend will be confirmed or violated
• Stop should be set at $62.75, approximately one ATR below the 50 SMA, giving the level room to be tested without being prematurely stopped on noise
• Momentum is broken - RSI collapsing, MACD crossed bearish - do not add into this setup
• 200 SMA climbing from $52 to $57.50 over three months confirms structural uptrend is intact
• Dividend yield of 3.9% provides reason for patience in a higher-for-longer rate regime
• Forward P/E of 9.82x is genuinely cheap relative to large-cap pharma peers
• Beta of 0.227 confirms defensive characteristics
• The next 2-4 weeks will likely be dominated by CAR-T news; technicals are timing mechanism, fundamental catalyst is directional driver
• If FDA issues class-wide guidance on CAR-T, BMY re-rates lower regardless of chart; if Arlo-cel progresses and Zola-cet returns to clean safety profile, BMY re-rates higher
• If $63.13 breaks, path to $60.40 and then $57.50 could be fast

→ vs aggressive: Stop at $62.89 sits below the 50 SMA, meaning invalidation would confirm the bearish case - not asymmetric upside

→ vs aggressive: Circular argument that market is 'already pricing in' CAR-T overhang - multiple compression means all risks could be priced in, not just one

→ vs aggressive: Should not add into broken momentum with collapsing RSI and bearish MACD crossing

→ vs conservative: Trimming 20-25% at $64.40 is premature - stock still trades above $63.13, 50 SMA not violated, 200 SMA uptrend intact, cutting winners at support is a cardinal sin of position management

→ vs conservative: Trim of 20-25% AND stop at $63.00 is double-counting risk - if trimming, don't need such a tight stop